DK3964502T3 - Psma-målretningsforbindelser og anvendelser deraf - Google Patents

Psma-målretningsforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK3964502T3
DK3964502T3 DK21198449.7T DK21198449T DK3964502T3 DK 3964502 T3 DK3964502 T3 DK 3964502T3 DK 21198449 T DK21198449 T DK 21198449T DK 3964502 T3 DK3964502 T3 DK 3964502T3
Authority
DK
Denmark
Prior art keywords
targeting compounds
psma targeting
psma
compounds
targeting
Prior art date
Application number
DK21198449.7T
Other languages
English (en)
Inventor
Martin G Pomper
Ronnie C Mease
Sangeeta Ray
Ying Chen
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3964502T3 publication Critical patent/DK3964502T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK21198449.7T 2009-03-19 2010-03-19 Psma-målretningsforbindelser og anvendelser deraf DK3964502T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16148409P 2009-03-19 2009-03-19
US16148509P 2009-03-19 2009-03-19
US24806709P 2009-10-02 2009-10-02
US24893409P 2009-10-06 2009-10-06
EP17169052.2A EP3222617B1 (en) 2009-03-19 2010-03-19 Psma-targeting compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK3964502T3 true DK3964502T3 (da) 2024-07-22

Family

ID=42740262

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21198449.7T DK3964502T3 (da) 2009-03-19 2010-03-19 Psma-målretningsforbindelser og anvendelser deraf
DK17169052.2T DK3222617T3 (da) 2009-03-19 2010-03-19 Psma-målretningsforbindelser og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17169052.2T DK3222617T3 (da) 2009-03-19 2010-03-19 Psma-målretningsforbindelser og anvendelser deraf

Country Status (13)

Country Link
US (4) US9056841B2 (da)
EP (5) EP2408755B1 (da)
CA (4) CA3131469A1 (da)
DK (2) DK3964502T3 (da)
ES (3) ES2988098T3 (da)
FI (1) FI3964502T3 (da)
HR (2) HRP20240952T1 (da)
HU (2) HUE059796T2 (da)
LT (2) LT3222617T (da)
PL (2) PL3222617T3 (da)
PT (2) PT3222617T (da)
SI (1) SI3964502T1 (da)
WO (1) WO2010108125A2 (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669127C (en) 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
PL3222617T3 (pl) 2009-03-19 2023-01-02 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2012135592A2 (en) 2011-03-31 2012-10-04 The Johns Hopkins University Theranostic imaging agents and methods of use
PL2739316T3 (pl) * 2011-08-05 2019-09-30 Molecular Insight Pharmaceuticals, Inc. Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty
US10011632B2 (en) 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
WO2013029011A2 (en) 2011-08-25 2013-02-28 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising a c-terminal bax peptide
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
CN107382890B (zh) * 2011-11-30 2021-01-29 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
HK1202256A1 (en) * 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
AU2013344778C1 (en) 2012-11-15 2024-06-27 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
FR2998298B1 (fr) 2012-11-21 2020-11-20 Univ Bourgogne Synthese de sels d’imidazo[1,2-a]pyrazin-4-ium pour la synthese du 1,4,7-triazacyclononane (tacn) et de ses derives n- et/ou c-fonctionnalises
CA2897437C (en) * 2013-01-14 2021-12-14 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
WO2014178878A1 (en) 2013-05-03 2014-11-06 Yale University Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer
WO2015057692A1 (en) * 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
US10406246B2 (en) 2013-10-17 2019-09-10 Deutsches Kresbsforschungszentrum Double-labeled probe for molecular imaging and use thereof
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CN105849568B (zh) * 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
US20170072072A1 (en) * 2014-03-18 2017-03-16 The Methodist Hospital System Ph sensitive fluorescent compounds and methods for tumor detection
CA2950892C (en) * 2014-05-06 2023-10-24 The Johns Hopkins University Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
EP3142710A4 (en) * 2014-05-16 2018-04-25 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
US10588972B2 (en) 2014-06-02 2020-03-17 Li-Cor, Inc. Phthalocyanine probes and uses thereof
EP3170003A4 (en) 2014-07-18 2018-03-28 University of Central Florida Research Foundation, Inc. Methods and compositions comprising a ct20 peptide
ES2912753T3 (es) 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
US9886665B2 (en) * 2014-12-08 2018-02-06 International Business Machines Corporation Event detection using roles and relationships of entities
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2016176462A1 (en) * 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20180158559A1 (en) * 2015-06-05 2018-06-07 Ncm Usa Bronx Llc Method and system for producing gallium-68 radioisotope by solid targeting in a cyclotron
PL3331892T3 (pl) * 2015-08-06 2019-11-29 Hoffmann La Roche Sposób wytwarzania pochodnych kwasu GalNAc
EP3337520A1 (en) * 2015-08-20 2018-06-27 Universität zu Köln Pain tracking by pet-imaging (pain-trap)
US10842887B2 (en) * 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
SI3356385T1 (sl) 2015-09-30 2021-04-30 Deutsches Krebsforschungszentrum 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate
WO2017075171A2 (en) 2015-10-27 2017-05-04 The Johns Hopkins University Pamam dendrimer based cest imaging agents and uses thereof
US10405753B2 (en) 2015-11-10 2019-09-10 Intuitive Surgical Operations, Inc. Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes
ES2848122T3 (es) 2015-11-16 2021-08-05 Hoffmann La Roche Fosforamidita de agrupación de GalNAc
RS62274B1 (sr) * 2016-03-22 2021-09-30 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
US20170296679A1 (en) * 2016-04-18 2017-10-19 Intuitive Surgical Operations, Inc. Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands
EP3900743A1 (en) 2016-07-14 2021-10-27 University Of Central Florida Research Foundation Incorporated Bi-dota complex-loaded dendritic polymer nanoparticles
US11147889B2 (en) * 2016-11-23 2021-10-19 Cancer Targeted Technology Llc Albumin-binding PSMA inhibitors
EP3544964B1 (en) 2016-11-28 2020-06-17 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
JP6867497B2 (ja) 2017-01-20 2021-04-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 回転可能な外科手術台
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2018215049A1 (en) 2017-05-23 2018-11-29 F. Hoffmann-La Roche Ag Process for galnac oligonucleotide conjugates
WO2018222778A1 (en) 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
JP7755371B2 (ja) 2017-06-09 2025-10-16 アヴェンセル ユーロップ ゲー・エム・ベー・ハー 共通キメラ抗原受容体発現免疫細胞のためのターゲティングモジュールならびに癌、感染および自己免疫障害の処置における使用
US11814365B2 (en) 2017-06-15 2023-11-14 The Johns Hopkins University PSMA targeted fluorescent agents for image guided surgery
EP3668518A1 (en) 2017-08-18 2020-06-24 Li-Cor, Inc. Sonodynamic therapy
AU2018355222B2 (en) * 2017-10-23 2024-10-03 The Johns Hopkins University Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)
AU2018363807B2 (en) 2017-11-13 2024-11-28 Deutsches Krebsforschungszentrum A double-labeled probe for molecular imaging and use thereof
EP3713606A1 (en) * 2017-11-21 2020-09-30 Deutsches Krebsforschungszentrum A double-labeled probe for molecular imaging and use thereof
CA3090495A1 (en) 2018-02-06 2019-08-15 The Johns Hopkins University Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
KR20210003135A (ko) 2018-04-17 2021-01-11 엔도사이트, 인코포레이티드 암의 치료 방법
EP3781019A4 (en) * 2018-04-17 2022-04-13 Cornell University COMPOSITIONS LABELED WITH FLUORINE -18 AND THEIR USE IN BIOLOGICAL TISSUE IMAGING
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy
EP3636635A1 (en) 2018-10-11 2020-04-15 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Imaging agents
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
MX2021009199A (es) 2019-01-30 2021-09-08 Coherent Biopharma Suzhou Ltd Conjugado de farmaco de dos ligandos y uso del mismo.
JP7604397B2 (ja) 2019-05-20 2024-12-23 エンドサイト・インコーポレイテッド Ｐｓｍａコンジュゲートの調製方法
CN113117099B (zh) * 2019-12-31 2022-07-15 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
US20230277698A1 (en) * 2020-07-23 2023-09-07 Technische Universität München Silicon-containing ligand compounds
AU2021320392A1 (en) * 2020-08-07 2023-03-09 The Johns Hopkins University Imaging and targeting programmed death ligand-1 (PD-L1) expression
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
US20230414762A1 (en) * 2020-11-17 2023-12-28 The Johns Hopkins University Prostate-specific membrane antigen (psma)-targeted prodrug for selective killing of cells expressing psma
CA3214045A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
WO2022216524A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
WO2024064969A2 (en) 2022-09-23 2024-03-28 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
WO2024143314A1 (ja) * 2022-12-27 2024-07-04 国立大学法人千葉大学 放射性標識医薬
AU2024208501A1 (en) 2023-01-10 2025-07-24 Sun Pharma Advanced Research Company Limited Ligand-drug conjugates
WO2025029963A1 (en) 2023-07-31 2025-02-06 Curium Us Llc [ 177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof
US12440585B2 (en) * 2023-09-12 2025-10-14 Curadel Surgical Innovations, Inc. Zwitterionic metal chelators
WO2025119908A1 (en) 2023-12-06 2025-06-12 Bracco Imaging Spa Psma-targeting fluorescent probes
WO2025163029A1 (en) 2024-01-31 2025-08-07 Bracco Imaging Spa Psma-targeting bimodal and heterobivalent fluorescent agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6159657A (en) 1999-08-31 2000-12-12 Eastman Kodak Company Thermal imaging composition and member containing sulfonated ir dye and methods of imaging and printing
EP1289571B1 (en) 2000-05-12 2004-07-21 University Hospital Prochelators of radiometal labeled molecules
US6663847B1 (en) 2000-10-13 2003-12-16 Mallinckrodt Inc. Dynamic organ function monitoring agents
WO2002041925A1 (en) 2000-11-24 2002-05-30 Breath Limited Sterilisation of pharmaceuticals
ATE443260T1 (de) 2002-01-10 2009-10-15 Univ Johns Hopkins Kontrastmittel und verfahren zum imaging von naaldase oder psma
FR2903952B1 (fr) 2006-07-21 2009-06-12 Renault Sas Dispositif et procede de surveillance de la commande du braquage de roue arriere directrice.
WO2008109832A2 (en) 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
CA2926573C (en) * 2007-06-26 2018-08-28 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US8562945B2 (en) * 2008-01-09 2013-10-22 Molecular Insight Pharmaceuticals, Inc. Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
JP2009169768A (ja) 2008-01-17 2009-07-30 Fuji Xerox Co Ltd 情報処理装置及びプログラム
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
PL3222617T3 (pl) * 2009-03-19 2023-01-02 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
CN107382890B (zh) * 2011-11-30 2021-01-29 约翰霍普金斯大学 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途
EP3601724B1 (en) 2017-03-28 2024-10-23 Baker Hughes Holdings LLC Wireline-deployed esp with self-supporting cable

Also Published As

Publication number Publication date
PL3964502T3 (pl) 2024-10-28
ES2636618T3 (es) 2017-10-06
US9776977B2 (en) 2017-10-03
EP2408755A2 (en) 2012-01-25
EP2408755B1 (en) 2017-05-03
CA2755965C (en) 2019-04-16
HUE059796T2 (hu) 2022-12-28
DK3222617T3 (da) 2022-10-03
CA3257131A1 (en) 2025-04-15
SI3964502T1 (sl) 2024-09-30
EP4420730A2 (en) 2024-08-28
PT3222617T (pt) 2022-09-30
CA2755965A1 (en) 2010-09-23
EP2408755A4 (en) 2012-09-12
HRP20221195T1 (hr) 2022-12-09
US9056841B2 (en) 2015-06-16
WO2010108125A3 (en) 2011-03-24
PL3222617T3 (pl) 2023-01-02
US20230348405A1 (en) 2023-11-02
EP3964498B1 (en) 2024-06-19
CA3035532A1 (en) 2010-09-23
PT3964502T (pt) 2024-07-22
HUE068042T2 (hu) 2024-12-28
US20150104387A1 (en) 2015-04-16
WO2010108125A2 (en) 2010-09-23
EP3222617B1 (en) 2022-07-06
CA3131469A1 (en) 2010-09-23
US11661402B2 (en) 2023-05-30
EP3964498A1 (en) 2022-03-09
ES2928480T3 (es) 2022-11-18
LT3222617T (lt) 2022-10-25
US20120009121A1 (en) 2012-01-12
EP3964502B1 (en) 2024-06-12
LT3964502T (lt) 2024-08-26
FI3964502T3 (fi) 2024-07-29
EP3222617A1 (en) 2017-09-27
EP4420730A3 (en) 2024-11-13
ES2988098T3 (es) 2024-11-19
EP3964502A1 (en) 2022-03-09
US20220259161A1 (en) 2022-08-18
HRP20240952T1 (hr) 2024-10-11
CA3035532C (en) 2021-10-26

Similar Documents

Publication Publication Date Title
DK3222617T3 (da) Psma-målretningsforbindelser og anvendelser deraf
DK2437790T3 (da) Konjugeringsfremgangsmåder
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
DK2414015T3 (da) Laryngoskopsystem
DK2411442T4 (da) Umættet polyesterresin
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
EP2445547A4 (en) CATHETERISM SYSTEM
EP2440486A4 (en) CABLE RETRACTION SYSTEM
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1008827A2 (pt) deisobutenizador
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
DE112010004249A5 (de) Spindelaktor
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
BR112012004964A2 (pt) girocóptero
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
DK2483126T3 (da) Skinnekøretøj
DE112010004865T8 (de) Lamellennassreibkupplung
DK2506968T3 (da) Faujasit-zeolit
DE112010003255A5 (de) Fördergutverteiler
BRPI1010159A2 (pt) bistuti
EP2398476A4 (en) Policosanol nanoparticles